Skip to main content
. 2020 Aug 1;20:315. doi: 10.1186/s12886-020-01584-w

Table 5.

Comparison of ocular surface parameters in the two groups at each timepoint of the study

BUT baseline 4 m 8 m 12 m 18 m
Cit-B12 10.1 ± 5.7 9.0 ± 5.9 9.7 ± 7.2 9.6 ± 4.7 9.8 ± 6.3
Placebo 8.6 ± 5.5 7.8 ± 5.0 7.4 ± 6.3 10.9 ± 6.5 9.4 ± 5.5
p 0.48 0.56 0.39 0.62 0.87
SCHIRMER baseline 4 m 8 m 12 m 18 m
Cit-B12 15.9 ± 8.9 14.8 ± 7.1 14.7 ± 7.7 16.5 ± 9.0 14.4 ± 9.2
Placebo 14.1 ± 8.8 14.8 ± 9.2 15.5 ± 7.6 17.5 ± 11.1 16.4 ± 11.0
p 0.59 0.99 0.80 0.83 0.66
CONJUNCTIVAL STAINING
baseline 4 m 8 m 12 m 18 m
Cit-B12 1.40 ± 0.60 1.60 ± 0.50 1.21 ± 0.42 1.11 ± 0.32 1.00 ± 0.47
Placebo 1.40 ± 0.70 1.40 ± 0.70 1.10 ± 0.57 1.13 ± 0.35 1.25 ± 0.46
p 0.99 0.43 0.60 0.89 0.22
CORNEAL STAINING
baseline 4 m 8 m 12 m 18 m
Cit-B12 0.20 ± 0.41 0.40 ± 0.50 0.21 ± 0.42 0.05 ± 0.23 0.11 ± 0.32
Placebo 0.30 ± 0.48 0.20 ± 0.42 0.10 ± 0.32 0.01 ± 0.00 0.13 ± 0.35
p 0.58 0.26 0.43 0.33 0.89
OSDI baseline 4 m 8 m 12 m 18 m
Cit-B12 9 ± 7 8 ± 7 7 ± 7 6 ± 5 8 ± 10
Placebo 13 ± 11 8 ± 6 7 ± 5 9 ± 7 8 ± 8
p 0.30 0.90 0.90 0.21 0.98